Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Papillomavirus Vaccines Clear all
Completed Phase 2 Interventional Results available

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

NCT01492582
View directory record Official record
Conditions
Cancer Survivor, Prevention of Human Papillomavirus Infection
Interventions
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58), laboratory biomarker analysis, survey administration, medical chart review
Biological · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years to 26 Years
Enrollment
1,499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Jul 21, 2026, 4:00 PM EDT
Completed No phase listed Observational

HPV Vaccine Hesitancy Among Indiana Youth With Cancer and Blood Diseases

NCT04667702
View directory record Official record
Conditions
Human Papilloma Virus Vaccine Hesitancy
Interventions
Interviews
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
9 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Not applicable Interventional

HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3

NCT02558803
View directory record Official record
Conditions
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6, Cervical Cancer, Genital Warts, Oropharyngeal Cancer
Interventions
Simple Reminder
Behavioral
Lead sponsor
Regenstrief Institute, Inc.
Other
Eligibility
11 Years to 17 Years
Enrollment
1,305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Jul 21, 2026, 4:00 PM EDT
Completed No phase listed Observational Results available

SDH of HPV Vaccine Completion

NCT03709602
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
3,076 participants
Timeline
2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Jul 21, 2026, 4:00 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Financial Incentives

NCT05744960
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Communication training, financial Incentive
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
9 Years to 12 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Recruiting Not applicable Interventional

ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention

NCT06535139
View directory record Official record
Conditions
Papillomavirus Vaccines
Interventions
Brief training, Parent-targeted motivational aids, Healthcare access
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
8 Years to 99 Years
Enrollment
4,630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Not applicable Interventional Results available

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

NCT00941889
View directory record Official record
Conditions
HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
Interventions
Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

NCT01424644
View directory record Official record
Conditions
Meningococcal Meningitis
Interventions
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Biological
Lead sponsor
Novartis
Industry
Eligibility
11 Years to 18 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Fremont, California • Madera, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

NCT05496231
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation, Gardasil 9
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years to 26 Years · Female only
Enrollment
1,080 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
39
States / cities
San Diego, California • Wheat Ridge, Colorado • Coral Gables, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 21, 2026, 4:00 PM EDT
Recruiting Phase 2 Interventional

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

NCT06157151
View directory record Official record
Conditions
Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer
Interventions
PRGN-2009 plus Pembrolizumab
Biological
Lead sponsor
Precigen, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Little Rock, Arkansas • Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MeFirst: A Tailored Intervention to HPV Vaccine Decision Making

NCT01769560
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma
Interventions
MeFirst Tailored Intervention
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
661 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

NCT00294047
View directory record Official record
Conditions
Infections, Papillomavirus, Papillomavirus Vaccines
Interventions
Cervarix, Placebo control
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
26 Years and older · Female only
Enrollment
5,752 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
36
States / cities
Fountain Valley, California • Aurora, Colorado • Golden, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Not applicable Interventional Results available

Virtual Immersive Communication Training on Recommending Immunizations

NCT04368455
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Virtual Immersive Communication Training on Recommending Immunizations (VICTORI), HPV Same Way Same Day App
Behavioral
Lead sponsor
Brittany Rosen
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Jul 21, 2026, 4:00 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

PREVENT HPV -Related Cancers Trial

NCT07217145
View directory record Official record
Conditions
HPV Vaccination, Uptake Vaccination, Series Completion
Interventions
PREVENT
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1,455 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

mHealth Intervention in Increasing HPV Vaccinations in College Students

NCT02960100
View directory record Official record
Conditions
Healthy Subject
Interventions
Informational Intervention, Media Intervention, Survey Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 25 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Jul 21, 2026, 4:00 PM EDT
Terminated Not applicable Interventional

Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care (ECA-HPV)- Clinical Trial

NCT06367699
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Usual Care, ECA-HPV App with Clinic Notification and Adolescent Functions Disabled, ECA-HPV App with Clinic Notification Function Enabled, ECA-HPV App with Adolescent Function Enabled, ECA-HPV App with Clinic Notification and Adolescent Functions Enabled
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
8 Years to 12 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose

NCT03943875
View directory record Official record
Conditions
Immunization, Efficacy, Human Papilloma Virus
Interventions
9-valent HPV vaccine, 2 dose efficacy, 9-valent HPV vaccine, 3 doses standard timing
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
15 Years to 26 Years
Enrollment
767 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)

NCT05677360
View directory record Official record
Conditions
Human Papilloma Virus (HPV) Vaccine
Interventions
HPV MISTICS -Provider Level, HPV MISTICS - Parent Level, HPV MISTICS- HPV Vaccine Champion Level
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jul 21, 2026, 4:00 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

NCT03036930
View directory record Official record
Conditions
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions
Biospecimen Collection, HPV Self-Collection, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Active, not recruiting Phase 4 Interventional

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT03023631
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Recombinant Human Papillomavirus Nonavalent Vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

NCT04646005
View directory record Official record
Conditions
Cervical Cancer
Interventions
Cemiplimab, ISA101b
Drug · Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Tucson, Arizona • Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 21, 2026, 4:00 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine

NCT04611022
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
HPV Educational Intervention
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 21, 2026, 4:00 PM EDT
Completed Not applicable Interventional

Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina

NCT01544764
View directory record Official record
Conditions
Adolescent Health Services, Immunization
Interventions
Assessment , Feedback, Incentives, and eXchange Program
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jul 21, 2026, 4:00 PM EDT
Active, not recruiting Not applicable Interventional

Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination

NCT05148559
View directory record Official record
Conditions
Papillomavirus Vaccines
Interventions
Reminder Sent Via Preferred Method of Communication, Reminder Sent Via Mailed Letter
Behavioral
Lead sponsor
Huong Nguyen, PhD
Other
Eligibility
12 Years to 12 Years
Enrollment
5,451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 21, 2026, 4:00 PM EDT